Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung

Journal of Thoracic and Cardiovascular Surgery

Volumn 139, Issue 4, 2010, Pages 984-990

  Shah, Sonam A ^a   Spinale, Francis G ^a   Ikonomidis, John S ^a   Stroud, Robert E ^a   Chang, Eileen I ^a   Reed, Carolyn E ^a  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; NEUTROPHIL COLLAGENASE;

ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASES;

EID: 77949470138     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2009.12.016     Document Type: Article

References (39)

1. Noël A., Jost M., and Maquoi E. Matrix metalloproteinases at cancer tumor-host interface. Sem Cell Dev Biol 19 (2008) 52-60
2. Egebad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 (2002) 161-174
3. Pritchard S.C., Nicolson M.C., Lloret C., McKay J.A., Ross V.G., Kerr K.M., et al. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. Oncol Rep 8 (2001) 421-424
4. Kodate M., Kasai T., Hashimoto H., Yasumoto K., Iwata Y., and Manabe H. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int 47 (1997) 461-469
5. Leinonen T., Pirinen R., Böhm J., Johansson R., Ropponen K., and Kosma V.-M. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, β-catenin and prognosis. Lung Cancer 51 (2006) 313-321
6. Sienel W., Hellers J., Morresi-Hauf A., Lichtinghagen R., Mutschler W., Jochum M., et al. Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 103 (2003) 647-651
7. Hofmann H.-S., Hansen G., Riehter G., Taege C., Simm A., Silber R.-E., et al. Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. Clin Cancer Res 11 (2005) 1086-1092
8. Heist R.C., Marshall A.L., Liu G., Zhou W., Su L., Neuberg D., et al. Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer. Clin Cancer Res 12 (2006) 5448-5453
9. Passlick B., Sienel W., Seen-Hibler R., Wöckel W., Thetter O., Mutschler W., et al. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 6 (2000) 3944-3948
10. Pinto C.A., de Oliveira Carvalho P.E., Antonângelo L., Garippo A., da Silva A.G., Soares F., et al. Morphometric evaluation of tumor matrix metalloproteinase 9 predicts survival after surgical resection of adenocarcinoma of the lung. Clin Cancer Res 9 (2003) 3098-3104
11. Thomas P., Khokha R., Shepherd F.A., Feld R., and Tsao M.-S. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol 190 (2000) 150-156
12. Liu H.L., Zhang T., Li X., Huang J., Wu B., Huang X., et al. Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer. Cancer Sci 99 (2008) 2185-2192
13. Overall C.M., and Kleifeld O. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6 (2006) 227-239
14. Leighl N.B., Paz-Ares L., Douillard J.-Y., Peschel C., Arnold A., Depierre A., et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 23 (2005) 2831-2839
15. Bissett D., O'Byrne K.J., von Pawel J., Gatzemeier U., Price A., Nicolson M., et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small cell lung cancer. J Clin Oncol 23 (2005) 842-849
16. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295 (2002) 2387-2392
17. Ikonomidis J.S., Jones J.A., Barbour J.R., Stroud R.E., Clark L.L., Kaplan B.S., et al. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan Syndrome. Circulation 114 1 Suppl (2006) I365-I370
18. Spinale F.G., Coker M.L., Heung L.J., Bond B.R., Gunasinghe H.R., Etoh T., et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102 (2000) 1944-1949
19. Mukherjee R., Lowry A.S., Allen R.A., Stroud M.R., Wharton J.M., Ikonomidis J.S., et al. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol 97 (2006) 532-537
20. Deschamps A.M., Yarbrough W.M., Squires C.E., Allen R.A., Dowdy K.B., McLean J.E., et al. Trafficking of the membrane type-1 matrix metalloproteinase (MT1-MMP) in ischemia and reperfusion: relation to interstitial MT1-MMP activity. Circulation 111 (2005) 1166-1174
21. Ford R.L., Mains I.M., Hilton E.J., Reeves S.T., Stroud R.E., Crawford F.A., et al. Endothelin-A receptor inhibition after cardiopulmonary bypass: cytokines and receptor activation. Ann Thorac Surg 86 (2008) 1576-1583
22. Gottschalk P.G., and Dunn J.R. The five-parameter logistic: a characterization and comparison with the four-parameter logistic. Anal Biochem 343 (2005) 54-65
23. Simi L., Andreani M., Davini F., Janni A., Pazzagli M., Serio M., et al. Simultaneous measurement of MMP9 and TIMP1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR. Lung Cancer 45 (2004) 171-179
24. Safranek J., Pesta M., Holubec L., Kulda V., Dreslerova J., Vrzalova J., et al. Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Res 29 (2009) 2513-2517
25. Buergy D., Weber T., Maurer G.D., Mudduluru G., Medved F., Leupold J.H., et al. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer 125 (2009) 894-901
26. Gentner B., Wein A., Croner R.S., Zeittraeger I., Wirtz R.M., Roedel F., et al. Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases. Anticancer Res 29 (2009) 67-74
27. Overall C.M., and Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 94 (2006) 941-946
28. Munshi H.G., and Stack M.S. Reciprocal interactions between adhesion receptor signaling and MMP regulation. Cancer Metastasis Rev 25 (2006) 45-56
29. Clark I.M., Swingler T.E., Sampieri C.L., and Edwards D.R. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 40 (2008) 1362-1378
30. Tutton M.G., George M.L., Eccles S.A., Burton S., Swift R.I., and Abulafi A.M. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer 107 (2003) 541-550
31. Langenkiöld M., Holmdahl L., Falk P., and Ivarsson M.-L. Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer. Colorectal Dis 20 (2005) 245-252
32. Ranuncolo S.M., Armanasco E., Cresta C., Bal De K., Joffe E., and Puricelli L. Plasma MMP-9 (92 kDa- MMP) activity is useful in the followup and in the assessment of prognosis in breast cancer patients. Int J Cancer 106 (2003) 745-751
33. Wu C.-Y., Wu M.-S., Chiang E.-P., Chen Y.-J., Chen C.-J., Chi N.-H., et al. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res 13 (2007) 2054-2060
34. Ramankulov A., Lein M., Johannsen M., Schrader M., Miller K., and Jung K. Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinoma. Cancer Sci 99 (2008) 1188-1194
35. Iizasa T., Fujisawa T., Suzuki M., Motohashi S.-I., Yasufuku K., Yasakawa T., et al. Elevated levels of circulating plasma matrix metalloproteinase-9 in non-small cell lung cancer patients. Clin Cancer Res 5 (1999) 149-153
36. Baker A.H., Edwards D.R., and Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115 (2002) 3719-3727
37. Visse R., and Nagase H. Matrix metalloproteinase and tissue inhibitors of metalloproteinases. Circ Res 92 (2003) 827-839
38. Aljada I.S., Ramnath N., Donohue K., Harvey S., Brooks J.J., Wiseman S.M., et al. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small cell lung cancer. J Clin Oncol 22 (2004) 3218-3229
39. Gouyer V., Conti M., Devos P., Zerimech F., Copin M.-C., Créme E., et al. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer 103 (2005) 1676-1684